{'fraction_non_alphanumeric': 0.024793388429752067, 'fraction_numerical': 0.0, 'mean_word_length': 5.321739130434783, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Patient-led research in amyotrophic lateral sclerosis: Quo vadis?

Patient-led trials are steadily claiming their place in modern neurological research. A popular paper on the effects of lithium in amyotrophic lateral sclerosis included a report on a clinical trial in humans. Subsequently, a follow-up study using patient-reported data did not confirm the original result, opening a scientific debate on how patient-reported data could contribute to neurological research. This review critically illustrates the major benefits and caveats of the current patient-led trials and presents recent U.S. and UK guidelines, which aim to the optimal incorporation of patient-reported outcomes in a reinvigorated research perspective.